RankAlpha logo
Back to Rankings

ADIL

AdialF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings company update modestly improved the operating narrative by linking AD04 to a potentially more flexible FDA evidentiary framework, lower possible Phase 3 burden, European partnership discussions, and longer-dated IP protection if granted [#8-K-2026-05-11].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
AD04's Phase 3 path is still dependent on ongoing regulatory discussions and final trial design, so the hoped-for reduction in trial burden is not yet secured [#8-K-2026-05-11] [#10-Q-2026-05-08].
Momentum
71
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $2.60 · Bear $0.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $26.00
Why
Momentum71 · Δ7d -
Value41 · Δ7d -17.7
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
71
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendSoftening
Δ7d
-17.7
Δ21d
-17.2
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 71.2 / Value 41.1 / Sentiment 0.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$5.25M
Beta
1.26
Shares Out
23.99M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.38
Rev YoY
-
EPS YoY
+78.5%
Gross Margin
-
Op Margin
-
Net Debt
-$3.75M
Current Ratio
4.34
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology